BridgeBio Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2834 http://bridgebio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma Inc

Hedge Funds Are Crazy About BridgeBio Pharma, Inc. (BBIO) - Jul 13th, 2021 2:42 pm
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Jul 12th, 2021 8:30 pm
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions - Jul 8th, 2021 11:30 am
BridgeBio Pharma Stock Sees Rising Relative Strength; Still Shy Of Key Threshold - Jul 1st, 2021 6:15 pm
10 Best Stocks to Buy According to DiDi (NYSE: DIDI)’s Early Investor Billionaire Zhang Lei - Jul 1st, 2021 4:59 pm
BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer - Jun 28th, 2021 11:10 pm
A Biotech Pro Exited Novavax Stock. Here Are Three Stocks It Bought. - Jun 19th, 2021 11:00 am
2 Top Biotech Stocks to Buy for Summer 2021 - Jun 5th, 2021 10:31 am
BridgeBio Stock Flashes Healthy 83 RS Rating - Jun 2nd, 2021 9:44 pm
FDA Approves BridgeBio Pharma's FGFR2 Inhibitor for Bile Duct Cancer - Jun 1st, 2021 12:02 pm
BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1 - Jun 1st, 2021 11:30 am
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma - Jun 1st, 2021 11:00 am
BridgeBio Pharma and Helsinn Group Obtain FDA Approval for TRUSELTIQ - Jun 1st, 2021 9:00 am
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia - May 14th, 2021 11:30 am
BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates - May 6th, 2021 1:15 pm
BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update - May 6th, 2021 11:30 am
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BridgeBio Pharma, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors - May 3rd, 2021 12:15 pm
Is BridgeBio Pharma Inc. (BBIO) A Smart Long-Term Buy? - Apr 30th, 2021 5:39 pm
Is BBIO Stock A Buy or Sell? - Apr 24th, 2021 4:40 pm
BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions - Apr 13th, 2021 11:45 am